Literature DB >> 1527264

Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observations.

F Schneider1, P Lutun, M Hasselmann, J C Stoclet, J D Tempé.   

Abstract

We report the hemodynamic improvements induced by intravenous methylene blue (MB), a guanylate cyclase inhibitor, in 2 patients with hyperdynamic septic shock treated with norepinephrine (NE) infusion, mechanical ventilation and hemodialysis. MB injection augmented the low vascular resistance, mean arterial pressure and induced a slight decrease of cardiac index, without any change of heart rate and pulmonary artery wedge pressure. Plasma cyclic GMP levels decreased without a significant change of atrial natriuretic factor levels. MB (2 mg.kg-1) induced a longer lasting improvement of circulatory failure without deleterious side effects, but did not prevent the occurrence of delayed multiorgan failure or subsequent death. These data suggest that in patients, severe sepsis-induced loss of vascular responsiveness to NE involves activation of soluble guanylate cyclase, possibly stimulated by enhanced nitric oxide production. Furthermore, these observations support the concept that pharmacological blockade of guanylate cyclase may improve hemodynamics but not survival rates.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527264     DOI: 10.1007/bf01706481

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  10 in total

1.  Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells.

Authors:  R Busse; A Mülsch
Journal:  FEBS Lett       Date:  1990-11-26       Impact factor: 4.124

Review 2.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

3.  Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations.

Authors:  W P Arnold; C K Mittal; S Katsuki; F Murad
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

4.  Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway.

Authors:  G Julou-Schaeffer; G A Gray; I Fleming; C Schott; J R Parratt; J C Stoclet
Journal:  Am J Physiol       Date:  1990-10

5.  Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo.

Authors:  C Thiemermann; J Vane
Journal:  Eur J Pharmacol       Date:  1990-07-17       Impact factor: 4.432

6.  Two cases of poisoning by contamination of nitrous oxide with higher oxides of nitrogen during anaesthesia.

Authors:  J Clutton-Brock
Journal:  Br J Anaesth       Date:  1967-05       Impact factor: 9.166

7.  Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta.

Authors:  W Martin; G M Villani; D Jothianandan; R F Furchgott
Journal:  J Pharmacol Exp Ther       Date:  1985-03       Impact factor: 4.030

8.  Cardiovascular parameters and scoring systems in the evaluation of response to therapy in sepsis and septic shock.

Authors:  G Pilz; K Werdan
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

9.  Hemodynamic determinants of mortality in human septic shock.

Authors:  A B Groeneveld; W Bronsveld; L G Thijs
Journal:  Surgery       Date:  1986-02       Impact factor: 3.982

10.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.

Authors:  R M Palmer; A G Ferrige; S Moncada
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

  10 in total
  15 in total

Review 1.  Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.

Authors:  R Salomão; O Rigato; A C Pignatari; M A Freudenberg; C Galanos
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

Review 2.  Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue.

Authors:  Julio C Rojas; Aleksandra K Bruchey; F Gonzalez-Lima
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

3.  Effect of methylene blue on middle cerebral artery flow velocity in a patient with severe sepsis following clipping of a cerebral aneurysm.

Authors:  David A Zygun; Peter G Bradley; David K Menon
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  Efficacy of methylene blue in an experimental model of calcium channel blocker-induced shock.

Authors:  David H Jang; Sean Donovan; Lewis S Nelson; Theodore C Bania; Robert S Hoffman; Jason Chu
Journal:  Ann Emerg Med       Date:  2014-10-23       Impact factor: 5.721

5.  Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock.

Authors:  B Gachot; J P Bedos; B Veber; M Wolff; B Regnier
Journal:  Intensive Care Med       Date:  1995-12       Impact factor: 17.440

6.  Continuous infusion of methylene blue for septic shock.

Authors:  G Brown; D Frankl; T Phang
Journal:  Postgrad Med J       Date:  1996-10       Impact factor: 2.401

7.  Methaemoglobin production in normal adults inhaling low concentrations of nitric oxide.

Authors:  J D Young; O Dyar; L Xiong; S Howell
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

8.  A severe case of vasoplegic shock following metformin overdose successfully treated with methylene blue as a last line therapy.

Authors:  Rachel Erin Graham; Michaela Cartner; James Winearls
Journal:  BMJ Case Rep       Date:  2015-07-06

9.  Plasma cyclic guanosine 3'-5' monophosphate concentrations and low vascular resistance in human septic shock.

Authors:  F Schneider; P Lutun; A Couchot; P Bilbault; J D Tempé
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

10.  Comparison of the ability of nicardipine, theophylline and zaprinast to restore cardiovascular haemodynamics following inhibition of nitric oxide synthesis.

Authors:  N A Herity; J D Allen; B Silke; A A Adgey
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.